Avotermin

Drug Profile

Avotermin

Alternative Names: Human recombinant TGF beta 3; Juvista; RN 1001

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Renovo
  • Developer Renovo; Shire
  • Class Recombinant proteins; Transforming growth factors
  • Mechanism of Action Transforming growth factor beta3 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Scars; Vascular restenosis

Most Recent Events

  • 03 Mar 2011 Shire terminates its licence for avotermin in USA, Canada and Mexico
  • 03 Mar 2011 Discontinued - Phase-III for Scars in Denmark (Intradermal)
  • 03 Mar 2011 Discontinued - Phase-III for Scars in France (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top